Utilization of anti‐Parkinson drugs in Australia: 1995–2009
Identifieur interne : 000102 ( Main/Exploration ); précédent : 000101; suivant : 000103Utilization of anti‐Parkinson drugs in Australia: 1995–2009
Auteurs : Samantha A. Hollingworth [Australie] ; Amanda Rush [Australie] ; Wayne D. Hall [Australie] ; Mervyn J. Eadie [Australie]Source :
- Pharmacoepidemiology and Drug Safety [ 1053-8569 ] ; 2011-05.
English descriptors
Abstract
Purpose: To examine trends in the prescribing of anti‐Parkinsonian drugs (APD) in Australia from 1995 to 2009. Methods: We analyzed the Medicare Australia and Drug Utilisation Sub‐Committee (DUSC) databases for prescription data for overall APD dispensed use from 1995. We were able to examine prescribing by gender, age, and type of prescriber between 2002 and 2009. Prescriptions were converted to defined daily doses (DDD)/1000 population/day using Australian Bureau of Statistics population data. Results: Dispensed use of levodopa + carbidopa remained steady from 1995 to 2009 (0.76–0.82 DDD/1000 population/day); levodopa + benserazide use increased from 0.34 to 0.55 DDD/1000 population/day. Since 2005 dispensed use of levodopa + carbidopa + entacapone has steadily increased, from 0.03 to 0.10 DDD/1000 population/day. In July 2009 levodopa + carbidopa was the most widely used agent, followed by levodopa + benserazide, then benztropine. Cabergoline increased from 1999, peaked in 2006, and thereafter declined. APD use peaked in males and females aged 60–69 years. Age‐adjusted utilization was slightly higher in males than females. Conclusions: The amount of levodopa dispensed has slowly increased with levodopa + benserazide increasing faster than levodopa + carbidopa. Use of cabergoline fell when pramipexole became available and the risk of ergot‐related serosal adverse effects was more widely appreciated. Use of centrally acting anti‐cholinergics decreased over a period of time when use of atypical anti‐psychotic agents increased. Copyright © 2011 John Wiley & Sons, Ltd.
Url:
DOI: 10.1002/pds.2114
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Utilization of anti‐Parkinson drugs in Australia: 1995–2009</title><author><name sortKey="Hollingworth, Samantha A" sort="Hollingworth, Samantha A" uniqKey="Hollingworth S" first="Samantha A" last="Hollingworth">Samantha A. Hollingworth</name></author><author><name sortKey="Rush, Amanda" sort="Rush, Amanda" uniqKey="Rush A" first="Amanda" last="Rush">Amanda Rush</name></author><author><name sortKey="Hall, Wayne D" sort="Hall, Wayne D" uniqKey="Hall W" first="Wayne D" last="Hall">Wayne D. Hall</name></author><author><name sortKey="Eadie, Mervyn J" sort="Eadie, Mervyn J" uniqKey="Eadie M" first="Mervyn J" last="Eadie">Mervyn J. Eadie</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:E6859C2E262862C6FD9A0C74E7103DF47E68A69C</idno><date when="2011" year="2011">2011</date><idno type="doi">10.1002/pds.2114</idno><idno type="url">https://api.istex.fr/document/E6859C2E262862C6FD9A0C74E7103DF47E68A69C/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">000B77</idno><idno type="wicri:Area/Main/Curation">000A31</idno><idno type="wicri:Area/Main/Exploration">000102</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Utilization of anti‐Parkinson drugs in Australia: 1995–2009</title><author><name sortKey="Hollingworth, Samantha A" sort="Hollingworth, Samantha A" uniqKey="Hollingworth S" first="Samantha A" last="Hollingworth">Samantha A. Hollingworth</name><affiliation wicri:level="1"><country xml:lang="fr">Australie</country><wicri:regionArea>The University of Queensland, School of Population Health, Herston</wicri:regionArea><wicri:noRegion>Herston</wicri:noRegion></affiliation></author><author><name sortKey="Rush, Amanda" sort="Rush, Amanda" uniqKey="Rush A" first="Amanda" last="Rush">Amanda Rush</name><affiliation wicri:level="1"><country xml:lang="fr">Australie</country><wicri:regionArea>The University of Queensland, School of Population Health, Herston</wicri:regionArea><wicri:noRegion>Herston</wicri:noRegion></affiliation></author><author><name sortKey="Hall, Wayne D" sort="Hall, Wayne D" uniqKey="Hall W" first="Wayne D" last="Hall">Wayne D. Hall</name><affiliation wicri:level="1"><country xml:lang="fr">Australie</country><wicri:regionArea>The University of Queensland, UQ Centre for Clinical Research, Herston</wicri:regionArea><wicri:noRegion>Herston</wicri:noRegion></affiliation></author><author><name sortKey="Eadie, Mervyn J" sort="Eadie, Mervyn J" uniqKey="Eadie M" first="Mervyn J" last="Eadie">Mervyn J. Eadie</name><affiliation wicri:level="1"><country xml:lang="fr">Australie</country><wicri:regionArea>The University of Queensland, School of Medicine, Herston</wicri:regionArea><wicri:noRegion>Herston</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Pharmacoepidemiology and Drug Safety</title><title level="j" type="abbrev">Pharmacoepidem. Drug Safe.</title><idno type="ISSN">1053-8569</idno><idno type="eISSN">1099-1557</idno><imprint><publisher>John Wiley & Sons, Ltd</publisher><pubPlace>Chichester, UK</pubPlace><date type="published" when="2011-05">2011-05</date><biblScope unit="volume">20</biblScope><biblScope unit="issue">5</biblScope><biblScope unit="page" from="450">450</biblScope><biblScope unit="page" to="456">456</biblScope></imprint><idno type="ISSN">1053-8569</idno></series><idno type="istex">E6859C2E262862C6FD9A0C74E7103DF47E68A69C</idno><idno type="DOI">10.1002/pds.2114</idno><idno type="ArticleID">PDS2114</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1053-8569</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson's disease</term><term>anti‐Parkinson drugs</term><term>pharmacoepidemiology</term><term>prescribing</term><term>utilization</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Purpose: To examine trends in the prescribing of anti‐Parkinsonian drugs (APD) in Australia from 1995 to 2009. Methods: We analyzed the Medicare Australia and Drug Utilisation Sub‐Committee (DUSC) databases for prescription data for overall APD dispensed use from 1995. We were able to examine prescribing by gender, age, and type of prescriber between 2002 and 2009. Prescriptions were converted to defined daily doses (DDD)/1000 population/day using Australian Bureau of Statistics population data. Results: Dispensed use of levodopa + carbidopa remained steady from 1995 to 2009 (0.76–0.82 DDD/1000 population/day); levodopa + benserazide use increased from 0.34 to 0.55 DDD/1000 population/day. Since 2005 dispensed use of levodopa + carbidopa + entacapone has steadily increased, from 0.03 to 0.10 DDD/1000 population/day. In July 2009 levodopa + carbidopa was the most widely used agent, followed by levodopa + benserazide, then benztropine. Cabergoline increased from 1999, peaked in 2006, and thereafter declined. APD use peaked in males and females aged 60–69 years. Age‐adjusted utilization was slightly higher in males than females. Conclusions: The amount of levodopa dispensed has slowly increased with levodopa + benserazide increasing faster than levodopa + carbidopa. Use of cabergoline fell when pramipexole became available and the risk of ergot‐related serosal adverse effects was more widely appreciated. Use of centrally acting anti‐cholinergics decreased over a period of time when use of atypical anti‐psychotic agents increased. Copyright © 2011 John Wiley & Sons, Ltd.</div></front></TEI><affiliations><list><country><li>Australie</li></country></list><tree><country name="Australie"><noRegion><name sortKey="Hollingworth, Samantha A" sort="Hollingworth, Samantha A" uniqKey="Hollingworth S" first="Samantha A" last="Hollingworth">Samantha A. Hollingworth</name></noRegion><name sortKey="Eadie, Mervyn J" sort="Eadie, Mervyn J" uniqKey="Eadie M" first="Mervyn J" last="Eadie">Mervyn J. Eadie</name><name sortKey="Hall, Wayne D" sort="Hall, Wayne D" uniqKey="Hall W" first="Wayne D" last="Hall">Wayne D. Hall</name><name sortKey="Rush, Amanda" sort="Rush, Amanda" uniqKey="Rush A" first="Amanda" last="Rush">Amanda Rush</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000102 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000102 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:E6859C2E262862C6FD9A0C74E7103DF47E68A69C
|texte= Utilization of anti‐Parkinson drugs in Australia: 1995–2009
}}
| This area was generated with Dilib version V0.6.23. |  |